Big Moving Stock keep track of the biggest moving stocks in the market.
The Hot Industries
Specialty Chemicals 2
Air Delivery & Freight Services 1
REIT - Retail 1
The Hot Sectors
OSIR Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets. It operates in two segments, Biosurgery and Therapeutics. The Biosurgery segment develops, manufactures, and distributes biologic products for orthopedic, wound healing, and surgical procedures by harnessing the ability of cells and novel constructs for the body's natural healing. It offers Grafix for application to acute and chronic wounds, including diabetic foot ulcers and burns; and Ovation for use in surgical applications. This segment markets and distributes its products directly to hospitals and clinics, as well as through a network of distributors. The Therapeutics segment develops and markets products to treat medical conditions in the inflammatory and cardiovascular disease areas. It offers Prochymal for the treatment of refractory acute graft versus host disease in children. This segment also develops biologic stem cell drug candidates, such as Prochymal that is in clinical trials for various indications, including acute graft versus host disease in pediatric and adult patients, Crohn's disease, and acute myocardial infarction; and Chondrogen for osteoarthritis and cartilage protection. The company has a collaborative agreement with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
2015 Will Be The Year Nuo Therapeutics Shines14 Nov 2014, 11:00 amOn November 13, 2014, Nuo Therapeutics, Inc. (OTC:NUOT) reported financial results for the third quarter ending September 30, 2014. Revenues were driven by $1.20 million in product sales derived from both Angel and Aurix and $0.49 million in licensing fees, royalties, and other revenue related to the company’s licensing agreement and commercial partnership with Arthrex, Inc. signed in August ...
Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog11 Nov 2014, 9:20 amOsiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Osiris Therapeutics Beats on Q3 Earnings & Revenues11 Nov 2014, 6:00 amOsiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
Osiris posts 3Q profit7 Nov 2014, 6:09 amOn a per-share basis, the Columbia, Maryland-based company said it had profit of 2 cents. The developer of treatments using adult human mesenchymal stem cells posted revenue of $17.2 million in the period. ...
Osiris Therapeutics Announces Third Quarter 2014 Financial Results: Revenue up 29% and Company Turned Profitable7 Nov 2014, 6:00 amOsiris Therapeutics, Inc. , the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, ort